Experimental respiratory infection with type 4 adenovirus vaccine in volunteers: clinical and immunological responses.

摘要: ered acceptable or optimally effective [1, 2]. A living type 4 adenovirus (AV-4) vaccine developed by Chanock et al. [3] offers promise for control of type-specific disease. This entericcoated tablet has been administered orally to approximately 350,000 recruits several investigative groups over the past years, and shown in preventing ARD due AV-4 [4-6]. However, a study 1966 at Fort Dix, New Jersey, reduction following vaccination was followed increased incidence 7 (AV-7). Before introduction vaccine, this virus responsible insignificant amounts ARD; suppression AV-4, it predominated as cause respiratory disease, total rates approached those before immunization [5]. The same phenomenon